SCHEMBL10160337

SCHEMBL10160337

c1ccc(-c2ccc(-c3cccs3)cn2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.55
MAPT P10636 2/20 0.55
CYP2E1 P05181 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2A6 P11509 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2B6 P20813 1/20 0.52
FYN P06241 4/20 0.51
HPGDS O60760 2/20 0.47
ALDH1A1 P00352 3/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
HSD17B10 Q99714 2/20 0.46
HPGD P15428 2/20 0.46
GAA P10253 1/20 0.46
CASP1 P29466 1/20 0.46
MAPK10 P53779 1/20 0.46
CASP7 P55210 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CDK8 P49336 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18419721 0.93 FYN (0.52) KDM4EMAPTCYP2E1CYP3A4CYP2A6
SCHEMBL13917342 0.88 CYP2C9 (0.53) KDM4EMAPTCYP2E1CYP3A4CYP2A6
SCHEMBL10408880 0.86 KDM4E (0.52) KDM4EMAPTCYP2E1CYP3A4CYP2A6
SCHEMBL10726997 0.86 FYN (0.58) KDM4EMAPTCYP2E1CYP3A4CYP2A6
SCHEMBL12436893 0.84 CDK8 (0.46) KDM4EMAPTCYP2E1CYP3A4CYP2A6
SCHEMBL28373020 0.83 CYP2A6 (0.74) KDM4ECYP2E1CYP3A4CYP2A6CYP2C9
SCHEMBL12727899 0.82 KDM4E (0.52) KDM4EMAPTCYP2E1CYP3A4CYP2A6
SCHEMBL18078699 0.82 SMN1; SMN2 (0.51) KDM4EMAPTCYP2E1CYP3A4CYP2A6
SCHEMBL10964644 0.82 KDM1A (0.47) KDM4EMAPTCYP2E1CYP3A4CYP2A6
SCHEMBL10964561 0.80 KDM1A (0.46) KDM4EMAPTCYP2E1CYP3A4CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120046232-A1 COMPOSITIONS AND METHODS FOR REDUCING RELAPSE OF ADDICTIVE BEHAVIOR MEDICAL UNIVERSITY OF SOUTH CAROLINA 2012-02-23 US disclosed
US-7531541-B2 Partial mGluR5 antagonists for treatment of anxiety and CNS disorders VANDERBILT UNIVERSITY (US) 2009-05-12 US disclosed
US-20070208028-A1 Partial mGluR5 antagonists for treatment of anxiety and CNS disorders VANDERBILT UNIVERSITY 2007-09-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046232-A1 COMPOSITIONS AND METHODS FOR REDUCING RELAPSE OF ADDICTIVE BEHAVIOR GRM6, GRM5, GRM7 KDM4E 1271/4885MAPT 3237/4885CYP2E1 2692/4885
US-20070208028-A1 Partial mGluR5 antagonists for treatment of anxiety and CNS disorders GRM5, GRIK5, GRM1 KDM4E 853/4885MAPT 1347/4885CYP2E1 773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.